Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR OTCMKTS:IPCIF NASDAQ:LSTA NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$5.01+35.0%$3.02$7.96▼$24.15$25.27M0.6315,685 shs420,549 shsIPCIFIntellipharmaceutics International$0.00$0.00▼$0.15$4.96M1.5312,042 shs793,500 shsLSTALisata Therapeutics$2.33+1.1%$2.51$1.87▼$4.20$20.37M1.0130,845 shs9,022 shsTLPHTalphera$0.95-3.6%$0.53$0.38▼$1.20$19.39M-0.16979,098 shs118,583 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-4.63%-20.04%+50.81%+44.92%-78.78%IPCIFIntellipharmaceutics International0.00%0.00%0.00%0.00%0.00%LSTALisata Therapeutics+8.49%+4.55%-9.09%-8.15%-20.96%TLPHTalphera0.00%+14.89%+130.43%+101.23%+11.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$5.01+35.0%$3.02$7.96▼$24.15$25.27M0.6315,685 shs420,549 shsIPCIFIntellipharmaceutics International$0.00$0.00▼$0.15$4.96M1.5312,042 shs793,500 shsLSTALisata Therapeutics$2.33+1.1%$2.51$1.87▼$4.20$20.37M1.0130,845 shs9,022 shsTLPHTalphera$0.95-3.6%$0.53$0.38▼$1.20$19.39M-0.16979,098 shs118,583 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-4.63%-20.04%+50.81%+44.92%-78.78%IPCIFIntellipharmaceutics International0.00%0.00%0.00%0.00%0.00%LSTALisata Therapeutics+8.49%+4.55%-9.09%-8.15%-20.96%TLPHTalphera0.00%+14.89%+130.43%+101.23%+11.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AIPCIFIntellipharmaceutics International 0.00N/AN/AN/ALSTALisata Therapeutics 3.00Buy$23.50910.75% UpsideTLPHTalphera 3.50Strong Buy$5.00429.10% UpsideCurrent Analyst Ratings BreakdownLatest IPCIF, ALVR, TLPH, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025LSTALisata TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.007/15/2025LSTALisata TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $32.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AIPCIFIntellipharmaceutics International$660K0.00N/AN/A($0.32) per share0.00LSTALisata Therapeutics$1M20.37N/AN/A$3.49 per share0.67TLPHTalphera$650K29.83N/AN/A$0.47 per share2.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%11/10/2025 (Estimated)IPCIFIntellipharmaceutics International-$2.89M-$0.16N/AN/AN/AN/AN/AN/AN/ALSTALisata Therapeutics-$19.99M-$2.23N/AN/AN/AN/A-69.68%-59.44%11/11/2025 (Estimated)TLPHTalphera-$13M-$0.40N/AN/AN/AN/A-152.38%-64.32%11/12/2025 (Estimated)Latest IPCIF, ALVR, TLPH, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TLPHTalphera-$0.1150-$0.10+$0.0150-$0.10N/AN/A8/7/2025Q2 2025LSTALisata Therapeutics-$0.65-$0.54+$0.11-$0.54N/A$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AIPCIFIntellipharmaceutics InternationalN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78IPCIFIntellipharmaceutics InternationalN/AN/AN/ALSTALisata TherapeuticsN/A5.775.77TLPHTalpheraN/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%IPCIFIntellipharmaceutics InternationalN/ALSTALisata Therapeutics8.94%TLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%IPCIFIntellipharmaceutics International1.76%LSTALisata Therapeutics9.10%TLPHTalphera5.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableIPCIFIntellipharmaceutics International1033.09 million32.51 millionNot OptionableLSTALisata Therapeutics308.76 million7.96 millionNot OptionableTLPHTalphera1920.52 million19.35 millionOptionableIPCIF, ALVR, TLPH, and LSTA HeadlinesRecent News About These CompaniesShort Interest in Talphera, Inc. (NASDAQ:TLPH) Rises By 1,945.8%September 12, 2025 | americanbankingnews.comCorMedix makes $5M minority equity investment in TalpheraSeptember 9, 2025 | msn.comTalphera, Inc. (NASDAQ:TLPH) Sees Significant Drop in Short InterestSeptember 9, 2025 | americanbankingnews.comCorMedix Announces Strategic Minority Investment in TalpheraSeptember 8, 2025 | globenewswire.comTalphera, Inc. Earnings Call Highlights Strategic ProgressAugust 31, 2025 | tipranks.comTalphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trialAugust 27, 2025 | finance.yahoo.comTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal TrialAugust 25, 2025 | prnewswire.comTalphera, Inc. (NASDAQ:TLPH) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | insidermonkey.comTalphera, Inc.: Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | finanznachrichten.deTalphera Cuts Expenses 14 PercentAugust 15, 2025 | aol.comATalphera Reports Q2 2025 Financial Results and Study ProgressAugust 14, 2025 | tipranks.comTalphera, Inc. (TLPH) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comTalphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19MAugust 14, 2025 | msn.comTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | prnewswire.comA Preview Of Talphera's EarningsAugust 13, 2025 | benzinga.comTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025August 7, 2025 | prnewswire.comtalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPCIF, ALVR, TLPH, and LSTA Company DescriptionsAlloVir NASDAQ:ALVR$5.01 +1.30 (+35.04%) As of 09/16/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Intellipharmaceutics International OTCMKTS:IPCIFIntellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.Lisata Therapeutics NASDAQ:LSTA$2.33 +0.03 (+1.09%) As of 02:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Talphera NASDAQ:TLPH$0.94 -0.04 (-3.57%) As of 02:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Rezolute Stock: FDA Fast Track Fuels 2025 Breakout Lululemon’s Sell-Off Looks Overdone: A Contrarian Case This Defense Stock Is Up 113% This Year—Is It Still a Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
